Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Key Points

• The study assesses demographics of women receiving camizestrant combined with CDK4/6 inhibitors.
• Patient profiles include those treated with abemaciclib, palbociclib, or ribociclib for advanced breast cancer.
• Baseline characteristics outline the context of therapy for ER+ and HER2− patients.
• Findings can inform future treatment strategies in advanced breast cancer management.